The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Nucleic Acid Therapeutics is a leading peer-reviewed journal published by Mary Ann Liebert, Inc that focuses on the forefront of research in the fields of biochemistry, drug discovery, genetics, and molecular medicine. With an impressive Q1 ranking across multiple categories, including biochemistry and drug discovery, the journal aims to disseminate innovative findings on nucleic acid-based therapies, their mechanisms, and clinical applications. The journal is dedicated to advancing the understanding of nucleic acids in the development of new therapeutic strategies, appealing to a diverse audience of researchers, professionals, and students alike. Given its commitment to open access publishing, Nucleic Acid Therapeutics ensures that groundbreaking research is accessible, fostering collaboration and dialogue in this critical area of scientific inquiry. Situated in the United States, Nucleic Acid Therapeutics plays a pivotal role in connecting researchers and practitioners in the ever-evolving landscape of molecular medicine and biotechnology.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Frontiers in Molecular Biosciences is an esteemed open-access journal published by FRONTIERS MEDIA SA, based in Switzerland. Since its inception in 2014, the journal has made significant strides in the fields of biochemistry, genetics, and molecular biology, cementing its reputation with a solid position in the Q1 quartile for both Biochemistry and Genetics and Molecular Biology (miscellaneous) categories as of 2023. With a remarkable Scopus rank of #14/103 in the combined categories, it offers an essential platform for the dissemination of high-quality research that shapes the understanding of molecular processes and their implications in health and disease. The journal’s commitment to open access facilitates the broadest possible reach for groundbreaking discoveries, serving as a vital resource for researchers, professionals, and students alike. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, this journal continues to foster innovative discussions and advancements in molecular biosciences, paving the way for new insights and collaborations in the scientific community.

Biomolecules is a prestigious, peer-reviewed journal published by MDPI that has been dedicated to advancing the field of biochemical research since its launch in 2011. With an impressive impact factor positioning it in Q1 for Biochemistry and Q2 for Molecular Biology as of 2023, this journal serves as a vital platform for disseminating high-quality research findings related to biological macromolecules, including proteins, nucleic acids, and carbohydrates. Operating as an Open Access journal, it ensures that vital research is accessible to all, furthering knowledge dissemination and collaboration within the scientific community. Located in Basel, Switzerland, the journal has established a significant presence in major academic databases, holding commendable Scopus rankings in both Biochemistry and Molecular Biology. Researchers, professionals, and students will find Biomolecules an invaluable resource for cutting-edge research, reviews, and insights in the rapidly evolving domains of biochemistry and molecular biology.

The CRISPR Journal, published by MARY ANN LIEBERT, INC, is a pioneering platform dedicated to advancing the field of genetics and biotechnology through innovative research focused on CRISPR technology and its diverse applications. With an impressive Q1 ranking in both Biotechnology and Genetics for 2023, this journal is positioned among the leading publications in its field, showcasing groundbreaking studies from 2019 to 2024. While currently utilizing a subscription model, the journal's commitment to open science is reflected in its efforts to make high-quality research accessible to researchers, professionals, and students. The CRISPR Journal facilitates the dissemination of knowledge related to genomic editing technologies, fostering collaboration and advancing the understanding of gene manipulation, therapeutic techniques, and agricultural innovations. As a valuable resource for cutting-edge developments in the biochemistry and genetics landscape, this journal is essential for those seeking to stay at the forefront of CRISPR research and applications.

MOLECULAR BIOLOGY OF THE CELL is a prestigious journal published by the American Society for Cell Biology, focusing on the latest advancements in cell biology and molecular biology. Established in 1990, this journal serves as a vital forum for disseminating innovative research, methodologies, and insights that drive the understanding of cellular processes and their implications in health and disease. With a noteworthy impact factor and recognition within the top quartiles for both Cell Biology and Molecular Biology, it ranks prominently among its peers, with Scopus rankings reflecting its significance in the scientific community. Although the journal does not follow an open access model, it provides essential access options for both institutional and personal subscriptions. Researchers, professionals, and students seeking to expand their knowledge and collaborate on groundbreaking findings will find MOLECULAR BIOLOGY OF THE CELL an invaluable resource in the field.

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.